ABNOM
References
Q-switched Nd:YAG レーザーは、太田母斑および同様の症状を効果的に治療することが知られています。私たちは、皮膚を明るくすることなく、異常な領域の蒙古斑に high-fluence 1064 nm Q-switched Nd:YAG レーザーがどの程度効果があるかを調べる研究を実施しました。私たちはこれらの斑点を持つ 61 人の患者を調査し、合計 70 個の病変を検査しました。病変の半分はレーザーで治療されましたが、残りは比較のために未治療のままでした。私たちは、スケールとメラニンレベルを測定するMexameter®と呼ばれる装置を使用して結果を評価しました。患者は、治療群では平均14か月、観察群では平均18か月間追跡調査されました。研究の終わりに、治療群と未治療群の間でスケールスコアとメラニンレベルに有意な差があり、レーザー治療群の方が良好な結果を示したことがわかりました。 high-fluence Q-switched Nd:YAG レーザーは、皮膚の美白を引き起こすことなく、これらの異常なモンゴル斑点の治療に効果的かつ安全であることが証明されました。
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
私たちは、 ABNOM に対する特定のレーザー治療を使用する有効性と安全性を研究し、その効果にどのような要因が影響するかを検討しました。私たちは、 ABNOM を患い、2 ～ 9 回のレーザー治療を受けた 110 人の患者を調査しました。この治療は長く続ければ続けるほど効果があったが、高齢の患者には効果がなかったことがわかった。また、皮膚の色が薄く（III 型）、患部の面積が小さい（10 cm2 未満）患者にも効果がありました。 ABNOM に加えて肝斑があると、治療の効果が低下します。影響を受けた領域の色や数には違いがないようでした。約 10% の患者に治療後にシミが濃くなっています。早期の複数回の治療により良好な結果が得られました。肌の色が濃く、シミも濃い高齢の患者さんは、治療後にシミが濃くなる可能性が高くなります。 ABNOM および肝斑の患者の場合は、肝斑の悪化を避けるために低エネルギーのレーザーを使用する方が良いでしょう。
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ 処理
ホワイトニング剤が役立つことはほとんどありません。肝斑とは異なり、ABNOM はレーザー治療で改善することができ、再発することなく除去し続けることができます。 ABNOMを治療するには、レーザー治療を10〜20回行うことができます。
#QS1064 laser